DPP-4 inhibitors × adverse events & safety

TrialDiabetes, obesity & metabolism2018

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.

Yutaka Seino et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 308 people · 2018

Not counted

Probably lowered adverse events & safety

−1.13percentage points−1.32 to −0.94

As reported

difference −1.13 %, 95% CI −1.32 to −0.94

One number in the abstract

the abstract, start to end

difference [ETD] vs sitagliptin -1.13%, 95% confidence interval [CI]

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
−1.13−1.32 to −0.94
GLP-1 receptor agonistsDPP-4 inhibitorsAdverse events & safety
1 / 3

60 papers cite it

2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 28786547